These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 3731153)

  • 1. Pharmacokinetics of the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB3717) in the mouse.
    Newell DR; Alison DL; Calvert AH; Harrap KR; Jarman M; Jones TR; Manteuffel-Cymborowska M; O'Connor P
    Cancer Treat Rep; 1986 Aug; 70(8):971-9. PubMed ID: 3731153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of the thymidylate synthase inhibitor 2-desamino-N10-propargyl-5,8-dideazafolic acid and related compounds in murine (L1210) and human (W1L2) systems in vitro and in L1210 in vivo.
    Jackman AL; Taylor GA; O'Connor BM; Bishop JA; Moran RG; Calvert AH
    Cancer Res; 1990 Sep; 50(17):5212-8. PubMed ID: 2386929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formation and retention and biological activity of N10-propargyl-5,8-dideazafolic acid (CB3717) polyglutamates in L1210 cells in vitro.
    Sikora E; Jackman AL; Newell DR; Calvert AH
    Biochem Pharmacol; 1988 Nov; 37(21):4047-54. PubMed ID: 2461200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of cell death following thymidylate synthase inhibition: 2'-deoxyuridine-5'-triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole.
    Curtin NJ; Harris AL; Aherne GW
    Cancer Res; 1991 May; 51(9):2346-52. PubMed ID: 2015598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased thymidylate synthase in L1210 cells possessing acquired resistance to N10-propargyl-5,8-dideazafolic acid (CB3717): development, characterization, and cross-resistance studies.
    Jackman AL; Alison DL; Calvert AH; Harrap KR
    Cancer Res; 1986 Jun; 46(6):2810-5. PubMed ID: 2938731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The biochemical pharmacology of the thymidylate synthase inhibitor, 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583).
    Jackman AL; Newell DR; Gibson W; Jodrell DI; Taylor GA; Bishop JA; Hughes LR; Calvert AH
    Biochem Pharmacol; 1991 Oct; 42(10):1885-95. PubMed ID: 1741766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of anti-metabolite effects. Effects of thymidine on the efficacy of the quinazoline-based thymidylate synthetase inhibitor, CB3717.
    Jackman AL; Taylor GA; Calvert AH; Harrap KR
    Biochem Pharmacol; 1984 Oct; 33(20):3269-75. PubMed ID: 6487375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The renal effects of N10-propargyl-5,8-dideazafolic acid (CB3717) and a non-nephrotoxic analogue ICI D1694, in mice.
    Jodrell DI; Newell DR; Morgan SE; Clinton S; Bensted JP; Hughes LR; Calvert AH
    Br J Cancer; 1991 Nov; 64(5):833-8. PubMed ID: 1931603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
    Beland FA
    Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polyglutamation of the antifolate anticancer drug N10-propargyl-5,8-dideazafolic acid (CB 3717) in the mouse.
    Manteuffel-Cymborowska M; Sikora E; Grzelakowska-Sztabert B
    Anticancer Res; 1986; 6(4):807-12. PubMed ID: 2875688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thymidylate synthase: a target for anticancer drug design.
    Harrap KR; Jackman AL; Newell DR; Taylor GA; Hughes LR; Calvert AH
    Adv Enzyme Regul; 1989; 29():161-79. PubMed ID: 2633608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical effects of a quinazoline inhibitor of thymidylate synthetase, N-(4-(N-(( 2-amino-4-hydroxy-6-quinazolinyl)methyl)prop-2-ynylamino) benzoyl)-L-glutamic acid (CB3717), on human lymphoblastoid cells.
    Jackson RC; Jackman AL; Calvert AH
    Biochem Pharmacol; 1983 Dec; 32(24):3783-90. PubMed ID: 6661252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absorption, distribution, metabolism, and excretion of N,N-diethyl-M-toluamide in the rat.
    Schoenig GP; Hartnagel RE; Osimitz TG; Llanso S
    Drug Metab Dispos; 1996 Feb; 24(2):156-63. PubMed ID: 8742226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical pharmacology of CB30900, a novel dipeptide inhibitor of thymidylate synthase, in mice.
    Walton MI; Gibson W; Aherne GW; Lawrence N; Stephens TC; Smith MN; Jackman AL
    J Pharmacol Exp Ther; 1996 May; 277(2):909-16. PubMed ID: 8627573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man.
    Mizojiri K; Okabe H; Sugeno K; Misaki A; Ito M; Kominami G; Esumi Y; Takaichi M; Harada T; Seki H; Inaba A
    Arzneimittelforschung; 1997 Mar; 47(3):259-69. PubMed ID: 9105544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of an assay for the estimation of N10-propargyl-5,8-dideazafolic acid polyglutamates in tumor cells.
    Sikora E; Newell DR; Jackman AL; Simmonds AJ; Jones TR; Calvert AH
    Anal Biochem; 1988 Aug; 172(2):344-55. PubMed ID: 2461114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose dependent retention and polyglutamation of N10-propargyl-5,8-dideazafolic acid (CB 3717) in the tumour-bearing mouse.
    Manteuffel-Cymborowska M; Kaminska B; Grzelakowska-Sztabert B
    Anticancer Res; 1988; 8(4):791-6. PubMed ID: 3178167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor, N10-propargyl-5,8-dideazafolic acid, CB3717.
    Calvert AH; Alison DL; Harland SJ; Robinson BA; Jackman AL; Jones TR; Newell DR; Siddik ZH; Wiltshaw E; McElwain TJ
    J Clin Oncol; 1986 Aug; 4(8):1245-52. PubMed ID: 3734849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats.
    Cossum PA; Sasmor H; Dellinger D; Truong L; Cummins L; Owens SR; Markham PM; Shea JP; Crooke S
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1181-90. PubMed ID: 8166890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.